Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise against blood cancer in japanese trial

NCT ID NCT04661007

Ongoing Disease control Sponsor: Incyte Biosciences Japan GK Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the safety and effectiveness of tafasitamab, given alone or with other drugs (lenalidomide, parsaclisib, or R-CHOP), in about 72 Japanese adults with Non-Hodgkin lymphoma. The goal is to find the best doses and see if the treatment shrinks tumors. Participants have either relapsed/refractory or newly diagnosed disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma marginal zone lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA NON-HODGKINS LYMPHOMA

Contacts and locations

Locations

  • Aichi Cancer Center Hospital

    Aichi, 464 8681, Japan

  • Chiba Cancer Center

    Chiba, 260-8717, Japan

  • Iuhw Narita Hospital

    Narita, 286-8520, Japan

  • Japanese Red Cross Nagoya Daini Hospital

    Nagoya, 466-8650, Japan

  • Kanagawa Cancer Center

    Yokohama, 241-8515, Japan

  • Kindai University Hospital

    Sayama, 589-8511, Japan

  • Kobe City Medical Center General Hospital

    Hyōgo, 650-0047, Japan

  • Kyushu University Hospital

    Fukuoka, Japan

  • Mie University Hospital

    Tsu, 514-0001, Japan

  • National Cancer Center Hospital

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Chiba, 277-8577, Japan

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, 811-1395, Japan

  • Nho Disaster Medical Center

    Tachikawa, 190-0014, Japan

  • Nho Hokkaido Cancer Center

    Sapporo, 003-0804, Japan

  • Nho Kumamoto Medical Center

    Kumamoto-ken, 860-008, Japan

  • Nho Okayama Medical Center

    Okayama, 701-1192, Japan

  • Nho Shikoku Cancer Center

    Matsuyama, 791-0280, Japan

  • Osaka University Hospital

    Suita-shi, 565-0871, Japan

  • Saitama Medical Center

    Saitama-shi, 330-8503, Japan

  • The Cancer Institute Hospital of Jfcr

    Kōtoku, 135-8550, Japan

  • Tohoku University Hospital

    Miyagi, 980-8574, Japan

  • Tokai University Hospital

    Kanagawa, 259-1193, Japan

  • University of Fukui Hospital

    Fukui, 910-1193, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.